Company: IXHL
Filing Date: 2025-04-28
Form Type: 424B3
Source: 0001213900-25-036065
Chunk: 25

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: 424B3
Chunk 25
---
| ● | our expectations around feedback from and discussions with regulators, regulatory development paths and 
 with respect to Controlled Substances Act designation;                                                  |

| ● | our ability to maintain effective patent rights and other intellectual property protection for our drug                                  
 candidates, and to prevent competitors from using technologies we consider important to the successful development and commercialization 
 of our drug candidates;                                                                                                                  |

| ● | our ability to comply with applicable listing standards within the compliance period and to maintain the 
 listing of shares of our Common Stock on the Nasdaq Global Market;                                       |

| ● | our estimates regarding expenses, revenues, financial performance and capital requirements, including 
 the length of time our capital resources will sustain our operations;                                 |

| ● | our ability to commercialize drug candidates and to generate revenues; |

| ● | our financial condition, including our ability to obtain the funding necessary to advance the development 
 of our drug candidates and our ability to continue as a going concern;                                    |

| ● | our ability to comply with the provisions and requirements of our debt arrangements and to pay amounts 
 owed, including any amounts that may be accelerated;                                                   |

| ● | our ability to retain and attract qualified employees, directors, consultants and advisors; |

| ● | our ability to continue to comply with applicable privacy laws and protect confidential information from 
 security breaches;                                                                                       |

| ● | how recent and potential future changes in healthcare policy could negatively impact our business and 
 financial condition;                                                                                  |

| ● | the extent to which global economic and political developments, including existing regional conflicts,                                     
 pandemics, natural disasters, and the indirect and/or long-term impact of inflation, will affect our business operations, clinical trials, 
 or financial condition; and                                                                                                                |

| ● | any statement of assumptions underlying any of the foregoing. |

Although forward-looking
statements in this prospectus, including the documents incorporated by reference herein and therein, and in any free writing prospectus
that we have authorized for use in connection with this offering, reflect the good faith judgment of our management, such statements can
only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and
uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking
statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically
addressed under the heading “Risk Factors” contained in this prospectus, the accompanying prospectus and